OncoMatch/Clinical Trials/NCT05806580
Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma
Is NCT05806580 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Relma-cel for relapsed or refractory b-cell lymphoma.
Treatment: Relma-cel — To observe the efficacy and safety of a second infusion of relma-cel injection in patients with relapsed or refractory B-cell lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 positive
Prior therapy
Must have received: CAR-T cell therapy (Relma-cel) — initial treatment
have completed initial treatment with Relma-cel
Must have received: disease assessment — post-initial Relma-cel treatment
must have undergone at least one disease assessment post-initial Relma-cel treatment
Must have received: lymphodepleting chemotherapy (fludarabine, cyclophosphamide)
Toxicity related to lymphodepleting chemotherapy (fludarabine and cyclophosphamide), except for hair loss, must have resolved to ≤ Grade 1 or returned to baseline levels before retreatment.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify